Literature DB >> 8898953

Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells.

E Vey1, D Burger, J M Dayer.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is a potent cytokine in inflammatory processes. A variety of mechanisms that modulate its activity have been described, one being its binding to soluble receptors (sTNFR). In this study, we demonstrate that human monocytic cells such as THP-1 respond to direct contact with a membrane preparation of stimulated HUT-78 cells by producing TNF-alpha and by releasing sTNFR-p75, but not sTNFR-p55, with different kinetics. TNF-alpha concentration peaked after 12 h of contact and then decreased, whereas sTNFR-p75 production increased progressively upon cell/cell contact. The decrease in TNF-alpha concentration is not due to trapping of TNF-alpha by its soluble receptors or other soluble or cell-associated molecules, but rather to a proteolytic activity associated to THP-1 cells. On the other hand, the increase in sTNFR-p75 release does not result from an increase in the cleavage of pre-existing cell-associated sTNFR-p75 but from an increase in TNFR-p75 expression, immediately followed by the cleavage of its extracellular domain. Phenylmethylsulfonylfluoride, a serine protease inhibitor, has a negative effect on both TNF-alpha degradation and sTNFR-p75 release by THP-1 cells. Thus, there may be an enzymatic activity associated to THP-1 cells that plays an important role in the neutralization of TNF-alpha activity both by degrading the molecule and by cleaving its receptors at the cell surface.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898953     DOI: 10.1002/eji.1830261021

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Blockade of T cell contact-activation of human monocytes by high-density lipoproteins reveals a new pattern of cytokine and inflammatory genes.

Authors:  Lyssia Gruaz; Céline Delucinge-Vivier; Patrick Descombes; Jean-Michel Dayer; Danielle Burger
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

2.  Enhancement of Mycobacterium tuberculosis-induced tumor necrosis factor alpha production from primary human monocytes by an activated T-cell membrane-mediated mechanism.

Authors:  J Warwick-Davies; A J Watson; G E Griffin; S Krishna; R J Shattock
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 3.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

4.  Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis.

Authors:  Joel A G van Roon; Sarita A Y Hartgring; Marion Wenting-van Wijk; Kim M G Jacobs; Paul-Peter Tak; Johannes W J Bijlsma; Floris P J G Lafeber
Journal:  Ann Rheum Dis       Date:  2006-12-21       Impact factor: 19.103

Review 5.  Role of interleukin 15 and interleukin 18 in inflammatory response.

Authors:  F Y Liew; I B McInnes
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

6.  Mononuclear phagocyte hydrolytic enzyme activity associated with cerebral HIV-1 infection.

Authors:  B B Gelman; D A Wolf; M Rodriguez-Wolf; A B West; A K Haque; M Cloyd
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

7.  HDL interfere with the binding of T cell microparticles to human monocytes to inhibit pro-inflammatory cytokine production.

Authors:  Rakel Carpintero; Lyssia Gruaz; Karim J Brandt; Anna Scanu; Dorothée Faille; Valery Combes; Georges E Grau; Danielle Burger
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

8.  T-cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NFkappaB: implications for rheumatoid arthritis.

Authors:  Jonathan T Beech; Evangelos Andreakos; Cathleen J Ciesielski; Patricia Green; Brian M J Foxwell; Fionula M Brennan
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.

Authors:  I González-Alvaro; A M Ortiz; C Domínguez-Jiménez; A Aragón-Bodi; B Díaz Sánchez; F Sánchez-Madrid
Journal:  Ann Rheum Dis       Date:  2008-10-28       Impact factor: 19.103

Review 10.  The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction.

Authors:  Danielle Burger; Jean-Michel Dayer
Journal:  Arthritis Res       Date:  2002-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.